Skip to main content



Cancer Screening Recommendations in Idiopathic Inflammatory Myopathy

Nov 28, 2022

Idiopathic inflammatory myopathy (IIM) is associated with increased risk of lung, ovarian, colorectal, lymphoma, breast, and naso-pharyngeal cancers, often within three years of disease onset. At ACR22, plenary abstract 0002, Oldroyd, et al, reviewed the 18 recommendations provided by the

Read Article
Fulvio et al. Labial gland US to identify lymphoma in Sjogrens. OMERACT score of 3 in 100% of lymphoma and 35% non-lymphoma @RheumNow #ACR22 Abstr#1254

ACR 2022 - Day 1 Report

Nov 13, 2022

The masses have returned to ACR22, a live, face-to-face, and virtual, meeting that began Saturday in Philadelphia. There were hassles and glitches, yet the education and sessions were as you’d expect with many good presentations worth recapping.

Read Article
pregnant, pregnancy, mother, fertility

Updates on Reproductive Health in Women with SLE

Nov 12, 2022

Is patient-administered cervical cancer screening an option for women with SLE? Should I prescribe estrogen containing contraceptives to SLE women with APL antibodies? What complications should I be aware of in pregnant women with SLE? Here are three abstracts that provide insight.

Read Article
BIOBADASAR study of cancer risk in RA patients with prev cancer treated with b/tsDMARD. No increased risk, but yet again abatacept numbers are making me slightly nervous! @rheumnow #ACR22 Abstr#0267
Cancer screening in myositis: the path has always been unclear and inconsistent Workable consensus recommendations @Dr_Alex_Oldroyd risk stratification but still extensive investigation burden for most now need to look at effectiveness including cost ABST0002 #ACR22 @RheumNow
#ACR22 Abstr#0002 @Dr_Alex_Oldroyd presented eminence-based recommendation for patients with inflammatory myopathy. Enhanced screening for those high risk. Studies needed to assess feasibility i.e. cost, positive and negative predictive value of test etc. @RheumNow
Consensus for #cancer screening in IIM Presented: How Often to Screen #Plenary #ACR22 @rheumnow #myositis
Consensus for #cancer screening in IIM Presented: What tests to order for screening #Plenary #ACR22 @rheumnow #myositis
Consensus for CA screening in IIM Presented: Risk factors to consider screening #Plenary #ACR22 @rheumnow #myositis
Risk stratification for cancer in myositis @RheumNow #ACR22 #Plenary
Some suggested screening tests for malignancy in myositis. Recommendations based on assessment of risk factors @RheumNow #ACR22 #Plenary
🔸DM pts who are anti-TIF-1 Ab+ have higher risk of malignancy 🔸Ovarian cancer - most common Really important to do cancer screening in #dermatomyositis #ACR22 @RheumNow

Avoid Abatacept in RA patients with a history of cancer?

The management of RA patients with a history of cancer continues to be an area of concern. General recommendations are to treat patients with a history of solid organ cancer as no different to any other RA patient. Recently, the ORAL-Surveillance study demonstrated evidence of a greater risk of

Read Article
Did You Know? FDA relaxed warnings on #sarcoma with #Forteo- can use more than 2 years ⁦@RheumNow⁩ #acr22 #acrreview #osteoporosis
RheumNow Podcast square

Women with Rheumatic Disease (11.4.2022)

Nov 04, 2022

Dr. Jack Cush reviews the news and journal articles from this past week on  New regulatory decisions about JAK inhibitors and why do women with rheumatic diseases have unfair outcomes?

  1. Population study shows among vaccinated gout pts, COVID breakthrough

Read Article

2022 CDC Clinical Practice Guideline on Opioid Prescribing

Nov 03, 2022

The CDC has updated its Guideline for Prescribing Opioids for Chronic Pain and includes recommendations for managing acute (duration of <1 month), subacute (duration of 1–3 months), and chronic (duration of >3 months) pain.

This guideline provides recommendations for clinicians

Read Article
TNF inhibitors Dont Increase Cancer Risk! 4592 RA pts:TNFi Rx (2296) vs matched DMARD Rx (2296) pts. TNFi had a lower cancer risk than DMARD Rx (IR 6.5 vs. 15.6 /1000PYs]). TNFi had Lower HR GI CA (0.432), breast CA (0.146), GU CA (0.220)
RheumNow Podcast square

Infections & Lupus (10.28.2022)

Oct 28, 2022

Dr. Jack Cush discusses the news and journal reports from the past week on RheumNow. This week more lupus nephritis, more drug induced lupus and more lupus infections that may kill. 

Read Article
RheumNow Podcast square

RheumNow Podcast – “That’s Not My Name” (10.7.2022)

Oct 07, 2022

Dr. Jack Cush goes off on "Untitling" (not using proper names/titles) in the clinic, in addition to reports on rheumatologist salaries, new drugs in phase 1-3 development and the range of COVID-19 MSK symptoms -- all from the past week on

  1. Microbiome analyses of

Read Article
Microbioime analyses of cancer patients suggests over abundance of fungi, expecially transcriptionally active Candida and is associated with gastrointestinal and lung cancers. Candida DNA is also predictive of reduced survival in GI cancers
Cancer Risk with Scleroderma Spanish Scleroderma Registry examined a large cohort of systemic sclerosis (SSc) patients showing an increased cancer risk, especially breast, lung, hematologic and colorectal cancer.
RheumNow Podcast square

Heavy Metal Rheumatology (9.23.2022)

Sep 23, 2022

Below are this week’s highlights from RheumNow, as discussed by Dr. Jack Cush. Thanks to all of you for your kind comments and great reviews of our weekly podcast. Please let us know how we can improve by emailing me or recording your suggestion using the "Ask Cush Anything" link on our website

Read Article
PSS.hands_.Raynauds.jpg (keep)

Cancer Risk with Scleroderma

Sep 22, 2022

Spanish Scleroderma Registry examined a large cohort of systemic sclerosis (SSc) patients showing an increased cancer risk, especially breast, lung, hematologic and colorectal cancer.

The registry included 1930 patients with SSc and were compared to a matched general population to derive the

Read Article
antibody (Keep)

Clinical Profiles Seen with NXP-2 Antibodies

Sep 20, 2022

A recent review of the myositis associated autoantibody NXP-2 profiles its clinical associations with dermatomyositis (DM), calcinosis, severe myositis and, in some reports, with cancer.

Read Article